Semaglutide and its analogs did not increase the risk of developing pancreatic cancer
Israeli scientists analyzed a cohort of more than half a million people and found no statistically significant association between taking glucagon-like peptide-1 receptor agonists and the development of pancreatic cancer in adults with type 2 diabetes mellitus
09.01.2024